Evidence map›Paper›PMID 42082379›Full record

ArticleLupus science & medicine2026

Efficacy of belimumab in patients with SLE and haematological manifestations: retrospective analysis from the BeRLiSS 2.0 cohort.

Greta Hulej, Federico Arru, Benedetta Bianchi, Alessandra Bortoluzzi, Luisa Brussino, Paola Castrignanò, Alberto Cauli, Lorenzo Cavagna, Elisabetta Chessa, Emanuele Chiara and 33 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors.

Greta HulejDepartment of Medicine, Rheumatology Unit, University of Padua, Padua, Veneto, Italy.
Federico ArruDepartment of Medicine, Rheumatology Unit, University of Padua, Padua, Veneto, Italy.
Benedetta BianchiDepartment of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Marche, Italy.ORCID 0000-0002-0362-0825
Alessandra BortoluzziDepartment of Medical Sciences, University of Ferrara, Ferrara, Emilia-Romagna, Italy.
Luisa BrussinoDepartment of Medical Sciences, University of Turin, Turin, Piedmont, Italy.
Paola CastrignanòDepartment of Transplantology, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy.
Alberto CauliDepartment of Medical Science and Public Health, University of Cagliari, Cagliari, Sardinia, Italy.
Lorenzo CavagnaDepartment of Internal Medicine, University of Pavia, Pavia, Lombardia, Italy.
Elisabetta ChessaDepartment of Medical Science and Public Health, University of Cagliari, Cagliari, Sardinia, Italy.
Emanuele ChiaraDepartment of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Friuli-Venezia Giulia, Italy.
Rossella De AngelisDepartment of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Marche, Italy.ORCID 0000-0001-5169-3511
Ginevra De MarchiDepartment of Medicine, University of Udine, Udine, Friuli-Venezia Giulia, Italy.
Roberto DepascaleDepartment of Medicine, Rheumatology Unit, University of Padua, Padua, Veneto, Italy.
Marco Di CarloDepartment of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Marche, Italy.
Giacomo EmmiDepartment of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Friuli-Venezia Giulia, Italy.ORCID 0000-0001-9575-8321
Isotta GalvagniRheumatology Unit, Department of Medicine, University of Verona, Verona, Veneto, Italy.
Michela GasparottoDepartment of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Friuli-Venezia Giulia, Italy.
Mariele GattoDepartment of Medicine, Rheumatology Unit, University of Padua, Padua, Veneto, Italy.ORCID 0000-0003-4012-1248
Roberto GerliRheumatology Unit, Department of Medicine & Surgery, University of Perugia, Perugia, Umbria, Italy.
Marcello GovoniDepartment of Medical Sciences, University of Ferrara, Ferrara, Emilia-Romagna, Italy.
Alberto Lo GulloUOSD Papardo, Hospital of Messina, Messina, Sicily, Italy.
Alessia NanoDepartment of Medicine, University of Udine, Udine, Friuli-Venezia Giulia, Italy.
Simone NegriniDepartment of Medical Sciences, University of Turin, Turin, Piedmont, Italy.ORCID 0000-0003-1267-4320
Silvia NovielloInternal Medicine 'Guido Baccelli', Department of Precision and Rigenerative Medicine and Ionian Area, Università degli Studi di Bari Aldo Moro, Bari, Puglia, Italy.
Giovanni OrsoliniRheumatology Unit, Department of Medicine, University of Verona, Verona, Veneto, Italy.
Giulia PazzolaDepartment of Transplantology, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy.
Matteo PigaDepartment of Medical Science and Public Health, University of Cagliari, Cagliari, Sardinia, Italy.
Luca QuartuccioDepartment of Medicine, University of Udine, Udine, Friuli-Venezia Giulia, Italy.ORCID 0000-0002-0134-6439
Maurizio RossiniRheumatology Unit, Department of Medicine, University of Verona, Verona, Veneto, Italy.
Carlo SalvaraniDepartment of Transplantology, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy.
Ettore SilvagniDepartment of Medical Sciences, University of Ferrara, Ferrara, Emilia-Romagna, Italy.
Elena SilvestriDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Tuscany, Italy.
Marianna TamussinDepartment of Medical Sciences, University of Ferrara, Ferrara, Emilia-Romagna, Italy.
Martina TizianDepartment of Medicine, Rheumatology Unit, University of Padua, Padua, Veneto, Italy.
Paola TomiettoDepartment of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Friuli-Venezia Giulia, Italy.
Maria Letizia UrbanDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Tuscany, Italy.
Angelo VaccaInternal Medicine 'Guido Baccelli', Department of Precision and Rigenerative Medicine and Ionian Area, Università degli Studi di Bari Aldo Moro, Bari, Puglia, Italy.
Filippo VesentiniDepartment of Medicine, Rheumatology Unit, University of Padua, Padua, Veneto, Italy.
Marisol BracalentiDepartment of Medicine, Rheumatology Unit, University of Padua, Padua, Veneto, Italy.
Roberta RamondaDepartment of Medicine, Rheumatology Unit, University of Padua, Padua, Veneto, Italy.
Andrea DoriaDepartment of Medicine, Rheumatology Unit, University of Padua, Padua, Veneto, Italy.ORCID 0000-0003-0548-4983
Luca IaccarinoDepartment of Medicine, Rheumatology Unit, University of Padua, Padua, Veneto, Italy.
Margherita ZenDepartment of Medicine, Rheumatology Unit, University of Padua, Padua, Veneto, Italy margherita.zen@unipd.it.ORCID 0000-0003-0835-1406

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the effectiveness of belimumab (BEL) in improving anaemia, thrombocytopenia, lymphopenia and leucopenia in patients with SLE.

methodsThe BeRLiSS (Belimumab in Real Life Setting Study) 2.0 cohort included patients with SLE from 14 Italian referral centres treated with BEL for active joint or skin involvement, based on physician judgement, between June 2013 and May 2024. Clinical and laboratory parameters were recorded at baseline and every 6 months. Patients were eligible if they had baseline haematological abnormalities defined according to British Isles Lupus Assessment Group (BILAG) (grade C or higher): haemoglobin (Hb) ≤10.9 g/dL, platelets (Plts) ≤149×10

resultsAt baseline, 76 patients had anaemia, 44 thrombocytopenia, 107 lymphopenia and 53 leucopenia. Hb levels increased significantly from 9.9±0.6 g/dL to 11.7±1.4 g/dL at month 48 (p<0.001). Platelet counts rose from 110.2±38.1×10

conclusionIn this real-world cohort, BEL treatment was associated with improvement in anaemia, thrombocytopenia, lymphopenia and leucopenia with over half of patients achieving normalisation of blood counts. Haematological responses were similar regardless of concomitant immunosuppressive therapy, supporting the role of BEL as a therapeutic option for haematological abnormalities in SLE.

Indexed as

Antibodies, Monoclonal, HumanizedImmunosuppressive AgentsLupus Erythematosus, SystemicAdultAnemiaFemaleHemoglobinsHumansItalyLeukopeniaLymphopeniaMaleMiddle AgedRetrospective StudiesThrombocytopeniaTreatment OutcomeAntibodies, Monoclonal, HumanizedbelimumabHemoglobinsImmunosuppressive AgentsBiological ProductsGlucocorticoidsHematologyLupus Erythematosus, Systemic

Identifiers

PMID42082379
PMCPMC13141197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.